title: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.
abstract: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab.
  
  
  
  We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis.
  
  
  
  This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study.
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Marc
authors.initials: M
authors.lastname: Uemura
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Faisal
authors.initials: F
authors.lastname: Fa'ak
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Cara
authors.initials: C
authors.lastname: Haymaker
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Natalie
authors.initials: N
authors.lastname: McQuail
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sirmans
authors.affiliation: Department of Pathology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Courtney W
authors.initials: CW
authors.lastname: Hudgens
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Lydia
authors.initials: L
authors.lastname: Barbara
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Chantale
authors.initials: C
authors.lastname: Bernatchez
authors.affiliation: Department of Pathology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Curry
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
authors.affiliation: Department of Pathology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Tetzlaff
authors.affiliation: Department of Melanoma Medical Oncology, University of Texas-MD Anderson Cancer Center, Houston, TX USA.
authors.forename: Adi
authors.identifier: 0000-0002-0153-0244
authors.initials: A
authors.lastname: Diab